Fig. 7

Fig. 7

Electrophysiological antiepileptic activity of (+)-FFA (A, E), (−)-FFA (B, F), (+)-norFFA (C, G) and (−)-norFFA (D, H) in the scn1Lab^−/− mutant model, and ( ±)-FFA (colored in blue, A–H) used as a positive control. (A–H) Noninvasive local field potential (LFP) recordings from the optic tectum of larvae pre-exposed to (+)-FFA, (−)-FFA, (+)-norFFA and (−)-norFFA for 22 h. Epileptiform discharges are quantified by the cumulative duration (mean ± SEM) (A–D) and frequency (mean ± SEM) (E–H) of events per 10-min recording. With 27–45 larvae for each VHC-treated group, and 10–16 larvae for each compound-treated group. Statistical analysis: Kruskal–Wallis testing with Dunn’s multiple comparisons. Significance levels: ^*p ≤ 0.05, ^**p ≤ 0.01, ^***p ≤ 0.001, ^****p ≤ 0.0001. WT wild type, VHC vehicle, FFA fenfluramine, norFFA norfenfluramine